Skip to main content
SpringerLink
Log in
Book cover

Leitlinien neuroleptischer Therapie pp 135–153Cite as

Kombinationsbehandlung bei Therapie mit Neuroleptika — Polypragmasie oder Notwendigkeit?

  • Conference paper

Zusammenfassung

Beim Einsatz von Psychopharmaka orientiert sich der Kliniker in erster Linie an den „Zielsymptomen“, weil man von einer syndromgerichteten Medikamentenwirkung ausgehen kann [23, 34, 39]. Grohmann [30] untersuchte das Verordnungsverhalten an einer Universitätsklinik und fand, daß bei 62,7% aller Behandlungen im Durchschnitt 2,7 Psychopharmaka verabreicht werden, was verständlich ist, da sich bei in sich heterogenen psychiatrischen Krankheitsbildern eine Kombinationsbehandlung mit verschiedenen Psychopharmaka oft geradezu aufdrängt. Im folgenden Abschnitt wird erörtert, bei welchen psychiatrischen Krankheitsbildern eine Kombinationstherapie sinnvoll, weil einer Monotherapie überlegen, und bei welchen sie nicht sinnvoll ist.

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Atsmon A, Blum I (1978) The discovery. In: Roberts E, Amacher P (eds) Propanolol and schizophrenia. Liss, New York, pp 5–38

    Google Scholar 

  2. Baastrup PC, Hollnagel P, Sörensen R, Schou M (1976) Adverse reactions in treatment with lithium carbonate and Haloperidol. JAMA 236:2645–2646

    Article  PubMed  CAS  Google Scholar 

  3. Baldessarini RJ, Lipinski JF (1967) Toxicity and side effects of antipsychotic, antimanic and antidepressant medications. Psychiatr Ann 6:484–493

    Google Scholar 

  4. Beber CR (1971) Psychotropic treatment of anxiety and depression in the elderly. A double blind study. J Flo Med Assoc 58:35–38

    CAS  Google Scholar 

  5. Becker RE (1970) Evaluation of an amitriptyline-perphenazine combination in chronic schizophrenia. Am J Psychiatry 127:827–831

    PubMed  CAS  Google Scholar 

  6. Beckmann H, Haas S (1980) High dose Diazepam in schizophrenia. Psychopharmacology 71:79–82

    Article  PubMed  CAS  Google Scholar 

  7. Bennet JA, Hirschowitz, Zemlan F, Thurman DN, Garver DL (1984) Combined thioridazine and desipramine: early antidepressant response. Psychopharmacology 82:263–265

    Article  Google Scholar 

  8. Biedermann J, Lerner Y, Belmaker RH (1979) Combination of lithium carbonate and haloperidol in schizoaffective disorders. Arch Gen Psychiatry 35:327–333

    Article  Google Scholar 

  9. Brodie NH, McGhie RL, O’Hara J et al. (1985) Separate and combined anxiolytic and antidepressant treatment of mixed anxiety/depression. Acta Psychiatr Scand 72:81–88

    Google Scholar 

  10. Carlsen M (1978) Mechanism of the action of neuroleptic drugs. In: Liptin MA, Di Mascio D, Killam KF (eds) Psychopharmacology: a generation of progress. Raven, New York, pp 1057–1070

    Google Scholar 

  11. Carman JS, Bigelow LB, Wyatt RJ (1981) Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J Clin Psychiatry 42:142–148

    Google Scholar 

  12. Casey JF, Hollister LE, Klett CJ, Lasky JJ, Caffey EM (1961) Combined drug therapy of chronic schizophrenic. Am J Psychiatry 117:997–1003

    PubMed  CAS  Google Scholar 

  13. Chien CP, Cole JO (1973) Depot phenothiazine treatment in acute psychosis. Am J Psychiatry 130:13–17

    PubMed  CAS  Google Scholar 

  14. Chouinard G, Annable L, Serrano M, Albert JM, Charette R (1975) Amitriptyline-perphenazine interaction in ambulatory schizophrenic patients. Arch Gen Psychiatry 32:129–1307

    Article  Google Scholar 

  15. Cohen WJ, Cohen NH (1974) Lithium carbonate, haloperidol, and irreversible brain damage. J Am Med Assoc 230:1283–1287

    Article  CAS  Google Scholar 

  16. Collins AD, Dundas J (1967) A double-blind trial of amitriptyline-perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics. Br J Psychiatry 113:1425–1429

    Article  PubMed  CAS  Google Scholar 

  17. Cooper SF, Dugal R, Elie R, Albert JM (1979) Metabolic interaction between amitriptylin and perphenazine in psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 3:369–376

    CAS  Google Scholar 

  18. Creese J, Burt RD, Snyder HS (1978) Biochemic actions of neuroleptic drugs: Focus on the dopamine receptor. In: Iversen LL, Iversen SD, Snyder GS (eds) Handbook of psychopharmacology, vol 10: neuroleptics and schizophrenia. Plenum, New York London

    Google Scholar 

  19. Davis WG (1968) Treating psychical disturbances induced by physical disorders. A doubleblind study of perphenazine-amitriptyline in anxiety and depression. Psychosomatics 9:44–46

    PubMed  CAS  Google Scholar 

  20. Desiverio RV, Rickeis K, Weise CC et al. (1970) Perphenazine-amitriptyline in neurotic depressed outpatients: a controlled collaborative study. Am J Psychiatry 127:322–328

    Google Scholar 

  21. Eibergen RD, Carlson KR (1976) Pharmacol Biochem Behav 5:175–188

    Article  PubMed  CAS  Google Scholar 

  22. El-Yousse FMD, Manier DH (1974) Tricyclic antidepressants and phenothiazines. J Am Med Assoc 229:1419

    Google Scholar 

  23. Freyhan FA (1957) Psychomotilität, extrapyramidale Syndrome und Wirkungsweisen neuroleptischer Therapien (Chlorpromazin, Reserpin, Prochlorperazin). Nervenarzt 28:504–509

    PubMed  CAS  Google Scholar 

  24. General Practitioner Research Group (1967) Chlordiazepoxide with amitriptyline in neurotic depression. Practitioner 202:437–440

    Google Scholar 

  25. Glenn AG, Crayton JW, Klass DB, Evans H, Strizich M (1979) Lithium in chronic schizophrenia. Am J Psychiatry 136:454–455

    Google Scholar 

  26. Goodnick PJ, Meltzer HY (1983) Lithium treatment of schizomania and mania. Paper presented at the Annual Meeting of the American Psychiatric Association, New York, 1983, May 1–6

    Google Scholar 

  27. Gottfried K, Spring (1979) Neurotoxicity with combined use of lithium and thioridazine. J Clin Psychiatry 40:135–138

    Google Scholar 

  28. Gram LF, Overo FK (1972) Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J 1:463–465

    Article  PubMed  CAS  Google Scholar 

  29. Grohmann R, Dirschedl P, Rennig E, Scherer J, Schmidt LG (1986) Methodological problems in assessment of adverse drug reactions with drug combinations. Pharmacopsychiatry 19:300–301

    Article  Google Scholar 

  30. Grohmann R, Strauss A, Gehr C, Rüther E, Hippius H (1980) Zur Praxis der klinischen Therapie mit Psychopharmaka. Retrospektive Untersuchung der Verordnungsgewohnheiten in einer Psychiatrischen Universitätsklinik. Pharmacopsychiatry 13:1–19

    Article  CAS  Google Scholar 

  31. Hanlon TE, Ota KY, Agallianos DD, Bergmann SA, Bethan GD, Kobler F, Kurland AA (1969) Combined drug treatment of newly hospitalized acutely ill psychiatric patients. Dis Nerv Syst 30:104–116

    PubMed  CAS  Google Scholar 

  32. Hanlon TE, Ota KY, Kurland AA (1970) Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide and fluphenazine-imipramine. Dis Nerv Syst 31:171–177

    PubMed  CAS  Google Scholar 

  33. Hedberg DL, Houck JH, Glueck BC (1971) Tranylcypromine-trifluoperazine combination in the treatment of schizophrenia. Am J Psychiatry 127:114–1146

    Google Scholar 

  34. Hippius H (1976) The concept of „target symptoms“for drug treatment in psychiatry. In: Advances in the drug therapy of mental illness. WHO, Genf 1976, pp 79–82

    Google Scholar 

  35. Hordern A, Somerville DM (1962) Clinical trials in chronic schizophrenia. Med J Aust 1:40–43

    Google Scholar 

  36. Hordern A, Somerville DM, Krupinski J (1962) Does chronic schizophrenia respond to a combination of a neuroleptic and an antidepressant? J Nerv Ment Dis 134:361–376

    Article  PubMed  CAS  Google Scholar 

  37. Jimerson DC, Van Kämmen DP, Post RM, Docherty JP, Bunney We Jr (1982) Diazepam in schizophrenia: a preliminary double-blind trial. Am J Psychiatry 139:489–491

    PubMed  CAS  Google Scholar 

  38. Karson CN, Weinberger DR, Bigelow L, Wyatt RJ (1982) Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial. Am J Psychiatry 139:1627–1628

    PubMed  CAS  Google Scholar 

  39. Kielholz P (1971) Diagnose und Therapie der Depression für den Praktiker. Lehmann, München

    Google Scholar 

  40. Kuss HJ, Jungkunz G, Dieterle D (1980) Veränderungen der klinischen Wirkung des Amitriptylins durch Kombinationsbehandlung. Arzneiforsch/Drug Res 20:1200

    Google Scholar 

  41. Leonhard K (1986) Aufteilung der endogenen Psychosen und ihre differenzierte Ätiologie. 6. bearb. Auflage. Akademie, Berlin

    Google Scholar 

  42. Lindström LH, Persson E (1980) Propanolol in chronic schizophrenia: a controlled study in neuroleptic-treated patients. Br J Psychiatry 137:126–130

    Article  PubMed  Google Scholar 

  43. Mena A, Heistad G, Schiele BC, Janecek J (1964) A comparison of tranylcypromine alone with tranylcypromine plus trifluoperazine in the treatment of chronic outpatients. J Neuropsychiatry 5:542–550

    CAS  Google Scholar 

  44. Michaux MH, Kurland AA, Agalianos DD (1966) Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment of newly hospitalized, acutely ill psychiatric patients. CurrTherRes8 [Suppl]:117–152

    Google Scholar 

  45. Myers DH, Campbell PL, Cocks NM, Flowerdew JA, Muir A (1981) A trial of Propanolol in chronic schizophrenia. Br J Psychiatry 139:118–121

    Article  PubMed  CAS  Google Scholar 

  46. Nestoros JN, Nair NPV, Pulman JR, Schwartz G, Bloom D (1983) High doses of Diazepam improve neuroleptic-resistant chronic schizophrenic patients. Psychopharmacology 81:4–47

    Article  Google Scholar 

  47. Olivier-Martin R, Marzin D, Buschsenschutz E, Pichot P, Boissier AJ (1957) Concentrations plasmatiques de l’imipramine et de la desmethylimipramine et effet ante de-presseur au cours d’un traitement contrôle. Psychopharmacol 41:187–195

    Article  Google Scholar 

  48. Prusoff BA, Klermen GL (1983) Rapidity of symptom reduction in depressed outpatients treated with amitriptyline, perphenazine and amitriptyline/perphenazine. Psychopharmacol Bull 19:109–110

    Google Scholar 

  49. Püringer W, Kocher R, Gastpar M (1979) Zur Frage der Inkompatibilität einer Lithium-Neuroleptika Kombinationstherapie. Nervenarzt 50:124–127

    Google Scholar 

  50. Randy PJ, Ming T, Tsuang, Perry J (1977) Concomitant administration of Haloperidol and lithium carbonate in acute mania. Dis Nerv Syst 38:675–676

    Google Scholar 

  51. Rickeis KJ, Hutchinson CC, Weise et al. (1972) Doxepine and amitriptyline-perphenazine in mixed anxious-depressed neurotic outpatients: a collaborative controlled study. Psychopharmacologia (Berlin) 23:305–318

    Article  Google Scholar 

  52. Sassim N, Grohmann R (1988) Adverse drug reactions with Clozapine and simultaneous application of benzodiazepines. Pharmacopsychiatry 21:306–307

    Article  PubMed  CAS  Google Scholar 

  53. Schiele BC, Vestre NC, McNaughton DV (1963) Treatment of hospitalized schizophrenics with trifluoperazine plus tranylcypromine. Compr Psychiatry 4:66–79

    Article  PubMed  CAS  Google Scholar 

  54. Sedval G, Fyro B, Nyback H, Wiesel FA (1975) Actions of dopaminergic antagonists in the striatum. In: Calve DB, Chase TN, Barbeau A (eds) Advances in neurology, vol 9. Ravens, New York, pp 131–140

    Google Scholar 

  55. Seeman P, Chang-Wong, Sidney CHWM, Tedesco J, Wong K (1975) Brain receptors for antipsychotic drugs and dopamine: direct binding assay. Proc Natl Acad Sci USA 72:76–80

    Article  Google Scholar 

  56. Sharpley P, Mena A, Schiele BC, Heistad C (1964) A comparison of pargyline and tranylcypromine with and without the addition of trifluoperazine. Curr Ther Res 6:344–352

    PubMed  CAS  Google Scholar 

  57. Shepperd GP (1979) High dose propanolol in schizophrenia. Br J Psychiatry 134:470–476

    Article  Google Scholar 

  58. Shopsin B, Small JB, Kellams JJ, Milstein V, Moore JE (1976) Combining lithium and neuroleptics. Am J Psychiatry 133:980–981

    Google Scholar 

  59. Small IG, Kellams IJ, Milstein VA (1975) Placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 132:1315–1317

    PubMed  CAS  Google Scholar 

  60. Valle Jones JC, Craven JR, Wallis TD, Schiff AA (1983) Mixed anxiety/depressive illness in general practise: a therapeutic comparison of nomifensine with fluphenazine/nortriptyline. Acta Psychiatr Scand 68:494–500

    Article  Google Scholar 

  61. Vestre ND, Dehnel LL, Schiele BC (1969) A sequential comparison of amitriptyline, perphenazine and the amitriptyline-perphenazine combination in recently admitted anergic schizophrenics. Psychosomatics 10:296–303

    PubMed  CAS  Google Scholar 

  62. Yorkston NJ, Gruzelier JH, Zaki SA, Hollander D, Pitcher D, Sergeant NS (1977) Lancet 1:575

    Article  Google Scholar 

  63. Yorkston NJ, Malik MKU, Morrison RC, Harvard CWH (1974) Propanolol in the control of schizophrenic symptoms. Br Med JIV:633–635

    Google Scholar 

  64. Yorkston NJ, Zaki SA, Themen JFA, Havard CWH (1967) Propanolol to control schizophrenic symptoms: 55 patients. Adv Clin Pharmacol 12:91–104

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Psychiatrische Klinik und Poliklinik, Universitäts-Nervenklinik, Füchsleinstr. 15, D-8700, Würzburg, Deutschland

    Prof. Dr. E. Franzek & Dr. H. Beckmann

Authors
  1. Prof. Dr. E. Franzek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. H. Beckmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Klinik, Rheinische Landesklinik, Heinrich-Heine-Universität, Bergische Landstr. 2, 4000, Düsseldorf 12, Deutschland

    Kurt Heinrich

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Franzek, E., Beckmann, H. (1990). Kombinationsbehandlung bei Therapie mit Neuroleptika — Polypragmasie oder Notwendigkeit?. In: Heinrich, K. (eds) Leitlinien neuroleptischer Therapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-93466-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93466-7_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-52723-7

  • Online ISBN: 978-3-642-93466-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation